Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE: WAT) reported Q1 2026 revenue of $1.267 billion, above guidance by $56 million, driven by $747 million organic revenue (13% as reported, 11% cc) and $520 million from the acquired Biosciences and Diagnostic Solutions businesses. Adjusted EPS was $2.70 (+20% YoY); GAAP EPS was a loss of $0.87 reflecting acquisition accounting. The company raised full‑year organic growth guidance to 6.5–8.0% and adjusted EPS guidance to $14.40–$14.60, and now expects acquired business revenue of $3.035 billion in 2026.
Waters Corporation (NYSE:WAT) will report Q1 2026 results and host a conference call on May 5, 2026 at 8:30 a.m. ET.
A live webcast will be available on Waters Investor Relations, and a replay will remain available through at least June 2, 2026.
Waters (NYSE: WAT) launched the omniDAWN Multi-Angle Light Scattering (MALS) Photometer, the first extended-range MALS detector for UHPLC/UPLC workflows, available globally in summer 2026. The 18-angle detector enables up to 4x faster run times, 10x extended sizing (~50–500 nm radius), and reduces sample use by 30–50% and solvent use by ~40%.
Powered by ASTRA Software and integrating UV and RI detection, omniDAWN delivers absolute molar mass and size measurements for aggregates, viral vectors, LNPs, ADCs, and advanced materials; Empower compatibility is planned later this year.
Waters (NYSE: WAT) announced U.S. FDA clearance (April 8, 2026) of the Onclarity HPV Self-Collection Kit and FDA approval of the BD Onclarity HPV Assay for at-home use. The assay provides extended genotyping (six individual types, three pooled groups) and works with the automated BD COR System.
The kit aims to increase screening access for unscreened or under-screened individuals (about 60% of cervical cancer cases) and will be available by prescription in coming months, covered by private insurance, Medicaid, and Medicare.
Waters (NYSE: WAT) priced a $3.5 billion offering of senior notes issued by subsidiary Augusta SpinCo, split across five tranches maturing 2027, 2029, 2031, 2033 and 2036 with coupon rates from 4.321% to 5.245% at 100% issue price.
Proceeds, together with cash on hand, are intended to repay the $3.5 billion delayed draw term loan; closing expected on or about March 23, 2026, subject to customary conditions.
Waters (NYSE: WAT) launched the ARES-G3 Rheometer on March 9, 2026, a next-generation TA Instruments product that boosts data capture and speeds up testing.
The instrument captures up to 25,000 data points per second, delivers up to 10x the data rate of its predecessor, and can cut standard test times by up to 80%, enabling faster workflows and reduced calibrations.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will speak in a fireside chat at the TD Cowen Health Care Conference on March 2, 2026 at 11:10 AM ET.
A live webcast will stream on the company's Events & Presentations investor site and a replay will be available for 90 days.
Waters (NYSE: WAT) launched 1 mm I.D. microflow LC columns with MaxPeak Premier Technology on February 17, 2026, for ACQUITY, BioResolve, and GTxResolve brands. The columns claim up to 2× higher sensitivity, use up to 75% less sample, and reduce solvent use by up to 4× versus 2.1 mm I.D. columns, improving recovery for small molecules, peptides, and oligonucleotides while enabling earlier reproducible results and global availability with immediate shipment.
BD (NYSE: BDX) completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation (NYSE: WAT) on Feb 9, 2026. BD received $4.0 billion in cash and shareholders received ~0.135 WAT shares per BDX share, with cash for fractions.
As of closing BD shareholders held 39.2% of the combined company (fully diluted). Based on WAT's Feb 6, 2026 close, the business was valued at $18.8 billion. BD expects to use $2.0 billion for an accelerated share repurchase and $2.0 billion to repay debt. Claire M. Fraser joined the Waters board and stepped down from the BD board.
Waters (NYSE: WAT) has completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader organized into four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. The transaction used a Reverse Morris Trust, and post-close ownership is Waters 60.8% and BD shareholders 39.2% on a fully diluted basis. Claire M. Fraser, Ph.D., joined the Waters Board, expanding it to 11 members. Barclays advised Waters; Kirkland & Ellis served as lead counsel.